Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia [PDF]
Antimicrobial Agents and Chemotherapy, 2020 Cefepime-enmetazobactam is a novel β-lactam–β-lactamase inhibitor combination with broad-spectrum antimicrobial activity against a range of multidrug-resistant Enterobacteriaceae . This agent is being developed for a range of serious hospital infections.
Shampa Das, Elena Mitsi, Jesús Reiné
exaly +9 more sources
Diagnostic algorithm for the detection of carbapenemases and extended-spectrum β-lactamases in carbapenem-resistant Pseudomonas aeruginosa [PDF]
Microbiology SpectrumPseudomonas aeruginosa can acquire carbapenem resistance through various mechanisms, including genomic mutations leading to the overexpression of efflux pumps, intrinsic AmpC-β-lactamase, and/or reduced permeability, and/or through the acquisition of ...
Stefano Mancini +10 more
doaj +4 more sources
Studies on enmetazobactam clarify mechanisms of widely used β-lactamase inhibitors
Proceedings of the National Academy of Sciences of the United States of America, 2022 SignificanceMicrobial resistance to β-lactam antibiotics mediated by β-lactamase–catalyzed hydrolysis is a major global health concern. Penam sulfones, which are structurally related to penicillins, inhibit clinically important serine β-lactamases (SBLs) by forming transiently stable covalent complexes, thereby protecting β-lactam antibiotics from ...
Pauline A Lang, Ritu Raj, Anthony Tumber
exaly +5 more sources
Amrita Journal of MedicineCefepime plus enmetazobactam represents a breakthrough novel combination of a β-lactam antibiotic and a β-lactamase inhibitor, which demonstrates extensive antibacterial activity against a wide range of both gram-positive and gram-negative bacteria.
Raja Chakraverty +2 more
doaj +3 more sources
P20 Evaluation of cefepime/enmetazobactam against MDR Enterobacterales [PDF]
JAC Antimicrob ResistAbstract Background Cefepime/enmetazobactam is a fourth generation cephalosporin in combination with a novel penicillanic acid sulfone ESBL inhibitor. Cefepime is stable to AmpC β-lactamases (class C) and OXA-48-like carbapenemases (class D) whilst enmetazobactam has activity against most class A β ...
Jennifer Richards +2 more
europepmc +3 more sources
Antimicrobial Agents and Chemotherapy, 2020 Third-generation cephalosporin (3GC)-resistant Enterobacteriaceae are classified as critical priority pathogens, with extended-spectrum β-lactamases (ESBLs) as principal resistance determinants. Enmetazobactam (formerly AAI101) is a novel ESBL inhibitor developed in combination with cefepime for empirical treatment ...
Fabian Bernhard +2 more
exaly +6 more sources
1945. Antibacterial activity of cefepime/enmetazobactam and comparator agents against U.S. Enterobacterales clinical isolates collected from 2019-2021 [PDF]
Open Forum Infect Dis, 2023 Abstract Background The investigational β-lactam/β-lactamase inhibitor combination of cefepime/enmetazobactam (FPE) met criteria for non-inferiority and superiority compared to piperacillin-tazobactam (PTZ) in a phase 3 clinical trial of adult patients with complicated urinary tract infections/acute ...
Adam Belley +3 more
europepmc +4 more sources
2529. Population pharmacokinetic models for cefepime and enmetazobactam derived from pooled Phase 1 to Phase 3 clinical studies [PDF]
Open Forum Infect Dis, 2023 Abstract Background The investigational β-lactam/β-lactamase inhibitor combination of cefepime (FEP)/enmetazobactam (ENM) met criteria for non-inferiority and superiority compared to piperacillin/tazobactam in a phase 3 clinical trial of adult patients with complicated urinary tract infections (cUTI ...
Jannik Vollmer +3 more
europepmc +4 more sources
Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians [PDF]
Pharmaceuticals, 2022 Bacterial resistance mechanisms are continuously and rapidly evolving. This is particularly true for Gram-negative bacteria. Over the last decade, the strategy to develop new β-lactam/β-lactamase inhibitors (BLs/BLIs) combinations has paid off and ...
Luigi Principe +11 more
doaj +3 more sources
Cefepime-Enmetazobactam: a novel β-Lactam/β-Lactamase inhibitor combination for complicated urinary tract infections [PDF]
International Journal of Basic & Clinical PharmacologyComplicated urinary tract infections (cUTIs) represent a significant global health challenge, particularly with the rising prevalence of extended-spectrum β-lactamase (ESBL)-producing pathogens. Cefepime-Enmetazobactam, approved in India in June 2024, represents a novel β-lactam/β-lactamase inhibitor combination specifically developed to address ...
Arunkumar Ramaraj +4 more
core +4 more sources